

Momenta Pharmaceuticals Inc (MNTA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/MADDD0259CBEN.html>

Date: June 2020

Pages: 56

Price: US\$ 125.00 (Single User License)

ID: MADDD0259CBEN

Abstracts

Momenta Pharmaceuticals Inc (MNTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company's marketed products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio includes biosimilar as well its own novel product candidates. The company utilizes its technology such as Sialylation platform and SIFbody platform for developing generic versions, biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. The company markets its products through its collaborative partners. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc Key Recent Developments

May 07,2020: Momenta Pharmaceuticals reports first quarter 2020 financial and operating results

Apr 02,2020: Momenta provides corporate update amid COVID-19 pandemic

Feb 26,2020: Momenta Pharmaceuticals reports fourth quarter and full year 2019 financial results

Jan 13,2020: Momenta provides year-end 2019 update and 2020 outlook

Jan 03,2020: Momenta Pharmaceuticals announces CFO transition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Momenta Pharmaceuticals Inc - Key Facts
Momenta Pharmaceuticals Inc - Key Employees
Momenta Pharmaceuticals Inc - Key Employee Biographies
Momenta Pharmaceuticals Inc - Major Products and Services
Momenta Pharmaceuticals Inc - History
Momenta Pharmaceuticals Inc - Company Statement
Momenta Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Momenta Pharmaceuticals Inc - Business Description
Product Category: Product Revenue
Performance
Product Category: Research and Development Revenue
Performance
Momenta Pharmaceuticals Inc - Corporate Strategy
Momenta Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Momenta Pharmaceuticals Inc - Strengths
Momenta Pharmaceuticals Inc - Weaknesses
Momenta Pharmaceuticals Inc - Opportunities
Momenta Pharmaceuticals Inc - Threats
Momenta Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Momenta Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 07, 2020: Momenta Pharmaceuticals reports first quarter 2020 financial and operating results

Apr 02, 2020: Momenta provides corporate update amid COVID-19 pandemic

Feb 26, 2020: Momenta Pharmaceuticals reports fourth quarter and full year 2019 financial results

Jan 13, 2020: Momenta provides year-end 2019 update and 2020 outlook

Jan 03, 2020: Momenta Pharmaceuticals announces CFO transition

Dec 13, 2019: Momenta Pharmaceuticals appoints Dr. Jane F. Barlow to board of directors

Oct 31, 2019: Momenta Pharmaceuticals reports third quarter 2019 financial and operating results

Sep 19, 2019: Momenta Pharmaceuticals appoints Dr. Donna Grogan to board of directors

Aug 02, 2019: Momenta Pharmaceuticals reports second quarter 2019 financial and operating results

May 02, 2019: Momenta Pharmaceuticals announces first quarter 2019 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Momenta Pharmaceuticals Inc, Key Facts
Momenta Pharmaceuticals Inc, Key Employees
Momenta Pharmaceuticals Inc, Key Employee Biographies
Momenta Pharmaceuticals Inc, Major Products and Services
Momenta Pharmaceuticals Inc, History
Momenta Pharmaceuticals Inc, Subsidiaries
Momenta Pharmaceuticals Inc, Key Competitors
Momenta Pharmaceuticals Inc, Ratios based on current share price
Momenta Pharmaceuticals Inc, Annual Ratios
Momenta Pharmaceuticals Inc, Annual Ratios (Cont...1)
Momenta Pharmaceuticals Inc, Interim Ratios
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Momenta Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Momenta Pharmaceuticals Inc, Performance Chart (2015 - 2019)

Momenta Pharmaceuticals Inc, Ratio Charts

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Coherus BioSciences Inc

Innovent Biologics Inc

Viela Bio Inc

EMD Serono Inc

AB Biosciences Inc

Teva Pharmaceutical Industries Ltd

Biogen Inc

Biocad

Amgen Inc

Sanofi

Synthon Pharmaceuticals Inc

I would like to order

Product name: Momenta Pharmaceuticals Inc (MNTA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/MADDD0259CBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MADDD0259CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970